title: Effects of intravenous oxygen on prostacyclin and thromboxane formation in patients with peripheral occlusive arterial disease.
abstract: Oxygen infusion is used in complementary medicine for treatment of peripheral occlusive arterial disease. The mechanism of action is unknown. Thus, we determined the effects of oxygen infusion on prostacyclin, thromboxane and nitric oxide synthesis. Twelve patients with peripheral occlusive arterial disease received oxygen 40 ml/d intravenously for 3 weeks. Study parameters, analyzed by gas chromatography-mass spectrometry on day 1, 3, 10, 16, 21: 2,3-dinor-6-oxo-PGF(1alpha), colour invisible 2,3-dinor-TXB2 and nitrate in one-hour-urine before and after oxygen infusion, reflecting prostacyclin, thromboxane and nitric oxide synthesis. Urinary 8-iso-PGF2alpha, indicating oxidative stress, was assessed in one patient. Urinary 2,3-dinor-6-oxo-PGF1alpha rose from baseline more than 4-fold after oxygen infusion. In contrast, urinary 2,3-dinor-TXB2 excretion remained unchanged. Oxygen infusion had no effect on urinary nitrate excretion. Urinary 8-iso-PGF(2alpha) was not influenced by oxygen infusion with and without diclofenac pretreatment. Our data demonstrate a shift of the prostacyclin/thromboxane ratio toward prostacyclin by oxygen infusion. Thus, a mechanism of action is provided and clinical trials with intravenous oxygen find a rational basis.
authors.affiliation: Institute of Clinical Pharmacology, Medizinische Hochschule Hannover, 30623, Germany. Stichtenoth.Dirk@mh-hannover.de
authors.forename: D O
authors.initials: DO
authors.lastname: Stichtenoth
authors.forename: F J
authors.initials: FJ
authors.lastname: Kreutzer
authors.forename: F M
authors.initials: FM
authors.lastname: Gutzki
authors.forename: D
authors.initials: D
authors.lastname: Tsikas
authors.forename: V
authors.initials: V
authors.lastname: Nowak
authors.forename: J C
authors.initials: JC
authors.lastname: Frölich
mesh_terms: D015121:6-Ketoprostaglandin F1 alpha / Q000031:analogs & derivatives* / Q000652:urine; D000368:Aged; D001157:Arterial Occlusive Diseases / Q000188:drug therapy / Q000652:urine*; D015237:Dinoprost / Q000031:analogs & derivatives*; D011464:Epoprostenol / Q000096:biosynthesis*; D028441:F2-Isoprostanes / Q000652:urine; D005260:Female; D008401:Gas Chromatography-Mass Spectrometry; D006801:Humans; D007262:Infusions, Intravenous; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D009566:Nitrates / Q000652:urine; D010100:Oxygen / Q000008:administration & dosage / Q000494:pharmacology*; D013929:Thromboxane B2 / Q000031:analogs & derivatives* / Q000652:urine*
chemical_list: D028441:F2-Isoprostanes; D009566:Nitrates; C075750:8-epi-prostaglandin F2alpha; D013929:Thromboxane B2; D015121:6-Ketoprostaglandin F1 alpha; C028965:2,3-dinor-thromboxane B2; C028290:2,3-dinor-6-ketoprostaglandin F1alpha; D015237:Dinoprost; D011464:Epoprostenol; D010100:Oxygen